A citation-based method for searching scientific literature

Y Kawaguchi, K Kono, K Mimura, F Mitsui, H Sugai, H Akaike, H Fujii. Br J Cancer 2007
Times Cited: 60







List of co-cited articles
314 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
28

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.
Mitsuhiko Hanawa, Shioto Suzuki, Yoh Dobashi, Tetsu Yamane, Koji Kono, Nobuyuki Enomoto, Akishi Ooi. Int J Cancer 2006
219
26

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma.
K Mimura, K Kono, M Hanawa, F Mitsui, H Sugai, N Miyagawa, A Ooi, H Fujii. Br J Cancer 2005
87
21

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma.
Kousaku Mimura, Koji Kono, Mitsuhiko Hanawa, Mirei Kanzaki, Atsuhito Nakao, Akishi Ooi, Hideki Fujii. Clin Cancer Res 2005
73
20

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.
Yoshihiko Kawaguchi, Koji Kono, Kousaku Mimura, Hidemitsu Sugai, Hidenori Akaike, Hideki Fujii. Int J Cancer 2007
138
18

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Maarten L Janmaat, Mariëlle I Gallegos-Ruiz, José A Rodriguez, Gerrit A Meijer, Walter L Vervenne, Dick J Richel, Cees Van Groeningen, Giuseppe Giaccone. J Clin Oncol 2006
167
16

Untangling the ErbB signalling network.
Y Yarden, M X Sliwkowski. Nat Rev Mol Cell Biol 2001
15

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
13

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma.
Patrapim Sunpaweravong, Somkiat Sunpaweravong, Puttisak Puttawibul, Winyou Mitarnun, Chan Zeng, Anna E Barón, Wilbur Franklin, Sherif Said, Marileila Varella-Garcia. J Cancer Res Clin Oncol 2005
94
13

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.
Uta Reichelt, Peer Duesedau, Maria Ch Tsourlakis, Alexander Quaas, Björn C Link, Paulus G Schurr, Jussuf T Kaifi, Stephanie J Gros, Emre F Yekebas, Andreas Marx,[...]. Mod Pathol 2007
148
13

Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
Howard Safran, Thomas Dipetrillo, Paul Akerman, Thomas Ng, Devon Evans, Margaret Steinhoff, David Benton, John Purviance, Lisa Goldstein, Umadevi Tantravahi,[...]. Int J Radiat Oncol Biol Phys 2007
97
13

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
11


Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.
L Gibault, J-P Metges, V Conan-Charlet, P Lozac'h, M Robaszkiewicz, C Bessaguet, N Lagarde, A Volant. Br J Cancer 2005
117
11


Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Tomislav Dragovich, Sheryl McCoy, Cecilia M Fenoglio-Preiser, Jiang Wang, Jacqueline K Benedetti, Amanda F Baker, Christopher B Hackett, Susan G Urba, Ken S Zaner, Charles D Blanke,[...]. J Clin Oncol 2006
244
10

Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Andreas P Sutter, Michael Höpfner, Alexander Huether, Kerstin Maaser, Hans Scherübl. Int J Cancer 2006
51
11


EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.
Qichun Wei, Lirong Chen, Liming Sheng, Hans Nordgren, Kenneth Wester, Jörgen Carlsson. Int J Oncol 2007
74
10

Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Kousaku Mimura, Koji Kono, Takanori Maruyama, Mitsuaki Watanabe, Shinichiro Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono,[...]. Int J Cancer 2011
47
12

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype,[...]. N Engl J Med 2004
8

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
Val Gebski, Bryan Burmeister, B Mark Smithers, Kerwyn Foo, John Zalcberg, John Simes. Lancet Oncol 2007
923
8

Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
Shinsuke Sato, Yoshiaki Kajiyama, Masahiko Sugano, Yoshimi Iwanuma, Hiroshi Sonoue, Toshiharu Matsumoto, Keisuke Sasai, Masahiko Tsurumaru. Int J Radiat Oncol Biol Phys 2005
34
14

HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival.
M Dreilich, A Wanders, D Brattström, S Bergström, P Hesselius, G Wagenius, M Bergqvist. Dis Esophagus 2006
41
12

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
James A Bonner, Paul M Harari, Jordi Giralt, Nozar Azarnia, Dong M Shin, Roger B Cohen, Christopher U Jones, Ranjan Sur, David Raben, Jacek Jassem,[...]. N Engl J Med 2006
8

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
David R Ferry, Mark Anderson, Kate Beddard, Simon Tomlinson, Paul Atherfold, Jolanta Obszynska, Rebecca Harrison, Janusz Jankowski. Clin Cancer Res 2007
102
8

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
Joel Tepper, Mark J Krasna, Donna Niedzwiecki, Donna Hollis, Carolyn E Reed, Richard Goldberg, Krystyna Kiel, Christopher Willett, David Sugarbaker, Robert Mayer. J Clin Oncol 2008
957
8

Humanization of an anti-p185HER2 antibody for human cancer therapy.
P Carter, L Presta, C M Gorman, J B Ridgway, D Henner, W L Wong, A M Rowland, C Kotts, M E Carver, H M Shepard. Proc Natl Acad Sci U S A 1992
8

Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
Satoshi Ishikura, Keiji Nihei, Atsushi Ohtsu, Narikazu Boku, Shuichi Hironaka, Kiyomi Mera, Manabu Muto, Takashi Ogino, Shigeaki Yoshida. J Clin Oncol 2003
269
8



A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
David H Ilson, David Kelsen, Manish Shah, Gary Schwartz, Douglas A Levine, Jeff Boyd, Marinela Capanu, Benjamin Miron, David Klimstra. Cancer 2011
75
8

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006
6

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren,[...]. N Engl J Med 2004
6

Esophageal cancer.
Peter C Enzinger, Robert J Mayer. N Engl J Med 2003
6

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Manish A Shah, Ramesh K Ramanathan, David H Ilson, Alissa Levnor, David D'Adamo, Eileen O'Reilly, Archie Tse, Robin Trocola, Lawrence Schwartz, Marinela Capanu,[...]. J Clin Oncol 2006
321
6

Novel targeted therapies for advanced esophageal cancer.
C-C Lin, K P Papadopoulos. Dis Esophagus 2007
10
40

c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma.
Masayuki Akamatsu, Toshiharu Matsumoto, Kuniyuki Oka, Shigetaka Yamasaki, Hiroshi Sonoue, Yoshiaki Kajiyama, Masahiko Tsurumaru, Keisuke Sasai. Int J Radiat Oncol Biol Phys 2003
67
6

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
C Pinto, F Di Fabio, S Siena, S Cascinu, F L Rojas Llimpe, C Ceccarelli, V Mutri, L Giannetta, S Giaquinta, C Funaioli,[...]. Ann Oncol 2007
230
6


Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.
Howard Safran, Thomas DiPetrillo, Ahmed Nadeem, Margaret Steinhoff, Umadevi Tantravahi, Ritesh Rathore, Harold Wanebo, Marilyn Hughes, Chris Maia, James Y Tsai,[...]. Cancer Invest 2004
43
9

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Federico Cappuzzo, Fred R Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini,[...]. J Natl Cancer Inst 2005
6

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Leonard B Saltz, Neal J Meropol, Patrick J Loehrer, Michael N Needle, Justin Kopit, Robert J Mayer. J Clin Oncol 2004
6

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, Jose Baselga, Richard Bell, Christian Jackisch,[...]. N Engl J Med 2005
6

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Natalia V Sergina, Megan Rausch, Donghui Wang, Jimmy Blair, Byron Hann, Kevan M Shokat, Mark M Moasser. Nature 2007
740
6


Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.
Akishi Ooi, Takuo Takehana, Xiaoling Li, Shioto Suzuki, Kazuyoshi Kunitomo, Hiroshi Iino, Hideki Fujii, Yasuhisa Takeda, Yoh Dobashi. Mod Pathol 2004
149
6

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
R A Clynes, T L Towers, L G Presta, J V Ravetch. Nat Med 2000
6

The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.
Abbas Ghaderi, Mohammad Vasei, S A Maleck-Hosseini, Behronz Gharesi-Fard, Maliheh Khodami, Mehrnoosh Doroudchi, Helmout Modjtahedi. Pathol Oncol Res 2002
16
25

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
Caroline J Witton, Jonathan R Reeves, James J Going, Timothy G Cooke, John M S Bartlett. J Pathol 2003
468
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.